C
CITIUS ONCOLOGY, INC.
CTORCIK 0001851484NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Sep 30
Period
FY 2025
Revenue
—
Net Income
$-24.76M
Total Assets
$100.94M
Equity
$44.87M
Shares Out
88.28M
Op. Cash Flow
$-5.49M
Business
CITIUS ONCOLOGY, INC. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its main product is LYMPHIR™ (denileukin diftitox), an engineered IL‑2‑diphtheria toxin fusion protein approved for persistent or recurrent cutaneous T‑cell lymphoma, and the company also supports investigator‑initiated immuno‑oncology combination trials. Key business activities include clinical development and regulatory affairs, in‑house U.S. commercialization and marketing operations, and licensing/partnering arrangements for ex‑U.S. territories. The company targets U.S. cancer centers and specialist prescribers while pursuing distribution and named‑patient programs across Europe, South America and the Middle East.
Summary from filing dated 2025-12-23
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenues | — | — | — | — | — | |
| Research and development | 6 | 5 | — | 4 | — | |
| General and administrative | 9 | 8 | 1 | 6 | 138,115 | |
| Stock-based compensation general and administrative | 8 | 7 | — | 2 | — | |
| Total Operating Expenses | 24 | 21 | — | 12 | — | |
| Operating Loss | −24 | −21 | −1 | — | −138,115 | |
| Interest income | 36,373 | — | — | — | — | |
| Interest expense | −218,032 | — | — | — | — | |
| Total Other Income (Expense), Net | −181,659 | — | 3 | — | 518,926 | |
| Loss before Income Taxes | −24 | −21 | — | −12 | — | |
| Income tax expense | 1 | 576,000 | — | 576,000 | — | |
| Net Loss | −25 | −21 | 2 | −13 | 380,811 | |
| Net Loss Per Share - Basic (in Dollars per share) | −0.34 | −0.31 | 0.27 | −0.19 | 0.12 | |
| Net Loss Per Share Diluted (in Dollars per share) | −0.34 | −0.31 | 0.27 | −0.19 | 0.12 | |
| Weighted Average Common Shares Outstanding Basic (in Shares) | 73 | 68 | 7 | 68 | 1 | |
| Weighted Average Common Shares Outstanding Diluted (in Shares) (in Shares) | 73 | 68 | 7 | 68 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 112 | — | — | — | |
| Inventory | 22 | 8 | — | — | — | |
| Prepaid expenses | 1 | 3 | 25,454 | 8 | 88,169 | |
| Total Current Assets | 28 | 11 | 58,200 | 8 | 377,344 | |
| In-process research and development | 73 | 73 | — | 40 | — | |
| Total Other Assets | 73 | 73 | — | 40 | — | |
| Total Assets | 101 | 84 | 73 | 48 | 68 | |
| Accounts payable | 13 | 4 | — | 1 | — | |
| License payable | 23 | 28 | — | — | — | |
| Accrued expenses | 4 | — | 375,886 | 259,071 | — | |
| Total Current Liabilities | 49 | 33 | 2 | 21 | 31,836 | |
| Deferred tax liability | 3 | 2 | — | 1 | — | |
| Total Liabilities | 56 | 38 | — | 22 | — | |
| Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding | — | — | — | — | — | |
| Common stock - $0.0001 par value; 400,000,000 and 100,000,000 shares authorized at September 30, 2025 and 2024, respectively; 83,513,442 and 71,552,402 shares issued and outstanding at September 30, 2025 and 2024, respectively | 8,351 | 7,155 | 167 | 6,750 | 242 | |
| Additional paid-in capital | 109 | 85 | — | 44 | — | |
| Accumulated deficit | −64 | −39 | −2 | −18 | 345,266 | |
| Total Stockholders Equity | 45 | 46 | −2 | 26 | 345,508 | |
| Total Liabilities and Stockholders Equity | 101 | 84 | 73 | 48 | 68 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Deferred income tax expense | 1 | 576,000 | — | 576,000 | — | |
| Inventory | −13 | −2 | — | — | — | |
| Prepaid expenses | — | −1 | 62,715 | −5 | −88,169 | |
| Accounts payable | 10 | 2 | — | 1 | — | |
| Accrued expenses | 4 | −259,071 | 349,051 | −801,754 | 25,988 | |
| Due to related party | 9 | 14 | — | — | — | |
| Net Cash (Used in) Provided By Operating Activities | −5 | 126,353 | −601,304 | — | −47,968 | |
| License payments | −6 | −5 | — | — | — | |
| Net Cash Used In Investing Activities | −6 | −5 | −1 | — | −67 | |
| Net proceeds from issuance of common stock | 15 | — | — | — | 66 | |
| Cash contributed by parent | — | 4 | — | — | — | |
| Merger, net | — | −3 | — | — | — | |
| Proceeds from issuance of note payable to related party | — | 4 | — | — | — | |
| Net Cash Provided By Financing Activities | 15 | 5 | 2 | — | 68 | |
| Net Change in Cash and Cash Equivalents | 4 | 112 | — | — | — | |
| IPR&D Milestones included in License Payable | — | 28 | — | — | — | |
| Capital Contribution of due to related party by parent | — | 33 | — | — | — | |
| Net Prepaid Manufacturing transferred to Inventory | 1 | 6 | — | — | — | |
| Interest Paid | 187,389 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro